Lin Xichen, CSO, reported an open-market or private sale at Structure Therapeutics Inc. involving 100.000000 shares for an estimated $4783.00. Reported holdings after the transaction were 0.000000 shares. The stored filing text includes a detected 10b5-1 reference.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
Form 4 relationship flags and nearby filing context
CHIEF SCIENTIFIC OFFICER
Reflects price per share in Ordinary Shares.
The Ordinary Shares were converted into American Depositary Shares as reported in Table II.
1/4 of the Ordinary Shares vested one year after July 22, 2019 (the "Vesting Commencement Date"); the balance of the Ordinary Shares vested in a series of 36 successive equal monthly installments meas…
This reflects the number of Ordinary Shares remaining under the share option following the partial exercise of the share option for 17,817 Ordinary Shares.
Each American Depositary Share is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The American Depositary Shares have no expiration date.
17,817 Ordinary Shares, which were acquired upon exercise of a share option, were converted into 5,939 American Depositary Shares.
The American Depositary Shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 26, 2026.
Reflects price per share in American Depositary Shares.
The weighted average sale price for the transaction reported was $45.8642 and the range of prices were between $45.63 and $46.38. Upon request by the SEC staff, the Issuer, or any security holder of t…
The weighted average sale price for the transaction reported was $47.2030, and the range of prices were between $46.80 and $47.76. Upon request by the SEC staff, the Issuer, or any security holder of…
0 other filings
0 recent txs